{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:14:05Z","timestamp":1762272845621,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Intramuscular (IM) injection of drugs is associated with high rates of injecting-related injuries and diseases. However, little is known about the role of this route of administration in heroin-assisted treatment. The aim of this study was to determine the prevalence of IM diacetylmorphine administration and associated complications as well as to explore patients\u2019 views and opinions on the topic and the underlying reasons for this practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The research site was a Swiss outpatient treatment centre specialised in heroin-assisted treatment. We conducted in-depth interviews with two patients who intramuscularly inject diacetylmorphine. Interviews were analysed qualitatively, and emerging themes were used to develop a 38-item questionnaire on IM injections. We then offered this questionnaire to all patients in the treatment centre.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five main themes emerged from the in-depth interviews: poor venous access, side effects, subjective effects, procedure for IM injection, and consideration of alternatives to IM. These themes covered the rationale for using this route of administration, complications, subjective effects of IM diacetylmorphine, hygiene and safety measures as well as alternative routes of administration. Fifty-three patients filled in the questionnaire. The lifetime prevalence of IM injections was 60.4% (<jats:italic>n<\/jats:italic>\u2009=\u200932) and 34.4% (<jats:italic>n<\/jats:italic>\u2009=\u200911) of the patients stated that IM injection was their primary route of administration. No participant reported using the IM route for street drugs. The main reason for IM injections was poor vein access. Other reasons given were time saving and less risk of injuries. Complications included induration of muscle tissue and pain, whereas more severe complications like thrombosis and infections of the injection site were reported much less often.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As the population of opioid-dependent individuals is aging and the deterioration of access veins is likely to increase, the frequency of IM injecting will equally increase. Even though our data show that the IM injection of diacetylmorphine in a clinical setting is a common practice and appears to be relatively safe, research on alternative routes of administration is needed to provide potentially less harmful alternative routes of administration in heroin-assisted treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-021-00584-3","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T14:02:24Z","timestamp":1639836144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["\u00abOne prick and then it\u00b4s done\u00bb: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Maximilian","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Eichenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-0331","authenticated-orcid":false,"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"584_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000068811","volume":"9","author":"F G\u00fcttinger","year":"2003","unstructured":"G\u00fcttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res. 2003;9:73\u20139.","journal-title":"Eur Addict Res"},{"key":"584_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2011.03749.x","volume":"107","author":"M Harris","year":"2012","unstructured":"Harris M, Rhodes T. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. Addiction. 2012;107:1090\u20136.","journal-title":"Addiction"},{"key":"584_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.drugpo.2015.04.009","volume":"26","author":"D Ciccarone","year":"2015","unstructured":"Ciccarone D, Harris M. Fire in the vein: heroin acidity and its proximal effect on users\u2019 health. Int J Drug Policy. 2015;26:1103\u201310.","journal-title":"Int J Drug Policy"},{"key":"584_CR4","first-page":"57","volume":"17","author":"M Vogel","year":"2015","unstructured":"Vogel M, D\u00fcrsteler K, Strasser J, Schmid O, M\u00fcller E, Himmelheber P, et al. Injektionen in die Leistenvene: Pr\u00e4valenz und Umgang in heroingest\u00fctzter Behandlung. Suchtmedizin. 2015;17:57\u201362.","journal-title":"Suchtmedizin"},{"key":"584_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/157488406775268219","volume":"1","author":"E Rook","year":"2006","unstructured":"Rook E, Huitema A, Brink W, Ree J, Beijnen J. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol. 2006;1:109\u201318.","journal-title":"Curr Clin Pharmacol"},{"key":"584_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugpo.2015.11.003","volume":"28","author":"VD Hope","year":"2016","unstructured":"Hope VD, Parry JV, Ncube F, Hickman M. Not in the vein: \u201cmissed hits\u201d, subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol United Kingdom. Int J Drug Policy. 2016;28:83\u201390.","journal-title":"Int J Drug Policy"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/ADM.0000000000000346","volume":"11","author":"KT Phillips","year":"2017","unstructured":"Phillips KT, Anderson BJ, Herman DS, Liebschutz JM, Stein MD. Risk factors associated with skin and soft tissue infections among hospitalized people who inject drugs. J Addict Med. 2017;11:461\u20137.","journal-title":"J Addict Med"},{"key":"584_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1086\/320879","volume":"33","author":"EL Murphy","year":"2001","unstructured":"Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case\u2013control study. Clin Infect Dis. 2001;33:35\u201340.","journal-title":"Clin Infect Dis"},{"key":"584_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/00952991003592311","volume":"36","author":"KT Phillips","year":"2010","unstructured":"Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in denver, colorado. Am J Drug Alcohol Abuse. 2010;36:92\u20137.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"584_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349.","journal-title":"Drug Alcohol Depend"},{"key":"584_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235350","author":"T Wright","year":"2020","unstructured":"Wright T, Hope V, Ciccarone D, Lewer D, Scott J, Harris M. Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0235350.","journal-title":"PLoS ONE"},{"key":"584_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1086\/313703","volume":"30","author":"IA Binswanger","year":"2000","unstructured":"Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30:579\u201381.","journal-title":"Clin Infect Dis"},{"key":"584_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1753-6405.2009.00407.x","volume":"33","author":"R Sweeney","year":"2009","unstructured":"Sweeney R, Conroy AB, Dwyer R, Aitken CK. The economic burden to the public health system of treating non-viral injecting-related injury and disease in Australia (a cost of illness analysis). Aust N Z J Public Health. 2009;33:352\u20137.","journal-title":"Aust N Z J Public Health"},{"key":"584_CR14","unstructured":"Mayring P. Combination and integration of qualitative and quantitative analysis. In: Forum Qual Soc Res., vol 2. 2001."},{"key":"584_CR15","unstructured":"Hiltebrand D, Dey M, Bolliger H, Schaub M. Heroingest\u00fctzte Behandlung in der Schweiz. Resultate der Erhebung 2017. 2019. https:\/\/www.zora.uzh.ch\/id\/eprint\/161620\/. Accessed 18 Sept 2021."},{"key":"584_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7547\/87507315-72-8-380","volume":"72","author":"SE Kirchenbaum","year":"1982","unstructured":"Kirchenbaum SE, Midenberg ML. Pedal and lower extremity complications of substance abuse. J Am Podiatry Assoc. 1982;72:380\u20137.","journal-title":"J Am Podiatry Assoc"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-597X-6-1","volume":"6","author":"KM D\u00fcrsteler-MacFarland","year":"2011","unstructured":"D\u00fcrsteler-MacFarland KM, Vogel M, Wiesbeck GA, Petitjean SA. There is no age limit for methadone: a retrospective cohort study. Subst Abus Treat Prev Policy. 2011;6:1\u20138.","journal-title":"Subst Abus Treat Prev Policy"},{"key":"584_CR18","first-page":"340","volume":"67","author":"B Frank","year":"2000","unstructured":"Frank B. An overview of heroin trends in New York City: Past, present and future. Mt Sinai J Med. 2000;67:340\u20136.","journal-title":"Mt Sinai J Med"},{"key":"584_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jat\/21.2.105","volume":"21","author":"G Skopp","year":"1997","unstructured":"Skopp G, Ganssmann B, Cone EJ, Aderjan R. Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. J Anal Toxicol. 1997;21:105\u201314.","journal-title":"J Anal Toxicol"},{"key":"584_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000516431","volume":"28","author":"M Vogel","year":"2022","unstructured":"Vogel M, K\u00f6ck P, Strasser J, Kalbermatten C, Binder H, D\u00fcrsteler KM, et al. Nasal opioid agonist treatment in patients with severe opioid dependence: a case series. Eur Addict Res. 2022;28:80\u20135.","journal-title":"Eur Addict Res."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00584-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T03:39:27Z","timestamp":1674099567000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00584-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee (Ethikkommission Nordwest- und Zentralschweiz) on 2 July 2019. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}